 |
|
 |
 |
         |
|
|
|
|
 |
    |
|
|
|
|
 |
  |
|
|
|
|
 |
     |
|
|
 |
|
 |
bbc consulting partners
He is internationally recognized as a researcher on signal transduction in the endocrine pancreas and on cellular biology of pancreatic islet hormone synthesis and secretion. He is the recipient of 1996 Scientific Achievement Award of the National Academy of Sciences of the Turkish republic. He is one of the founders of the NIH-funded Michigan Diabetes Research & Training Center at the University of Michigan. He has been a member of the Metabolism Study Section of the National Institutes of Health for many years, as well as of scientific review boards of various foundations. He has served on the editorial boards of numerous prestigious scientific journals, and as an editor of Endocrinology, a journal of the Endocrine Society. He has assisted the pharmaceutical industry in the design of clinical drug trials and has acted as the safety monitor for drug trials. For many years, he has been actively involved
in human research subject protection, and has been a member and more
recently the chairman of the Institutional Review Board for Human
Subject Research of the University of Michigan Medical School.
Dr. Jackson received an A.B. from Harvard and a Ph.D. from Stanford in molecular biology. As a post-doctoral fellow with Professor Paul Berg at Stanford, he was involved in the early development of recombinant DNA technology and is the first author on the first paper published on this important technology. In addition to Dr. Jackson’s research and development management activities, he has also had substantial responsibility for business and corporate development activities. He was a principal spokesperson for the corporate financing activities of each of the three biotechnology companies where he was employed. These activities, involving both public and private stock offerings and the establishment of joint ventures, raised approximately $98 million. While at DuPont and DuPont Merck, he played a central role in establishing four joint ventures and technology-based partnerships, and served on the Board of Directors or management committee of each. He also served on the Board of Directors of the Industrial Biotechnology Association, the predecessor of BIO. Dr. Jackson has a long-standing interest
in the public policy implications of developments in biotechnology.
He has testified on issues relating to biotechnology at hearings
of the U. S. Senate and House of Representatives and is co-editor
of the book The Recombinant DNA Debate.  David
J. Herzig, Ph.D. Dr.
Herzig served for more than 30 years with Parke-Davis Pharmaceutical
Research Division of Warner-Lambert Co. During this time, he was
responsible for research in immunopharmacology, including the development
of new drugs for treating allergies, asthma, arthritis and other
immune diseases.
Dr. Herzig was also responsible for the identification, evaluation and licensing of compounds for Warner-Lambert to acquire for development on a worldwide basis. He maintained regular contact with all of the major European and Japanese research-based pharmaceutical companies. He was responsible for acquiring several compounds, including Rezulin and zenarestat. As vice president of drug development and scientific development—a position he held from 1994 until he retired in 1999—Dr. Herzig was responsible for all aspects of development, registration and preparation for launch of drugs for diabetes, hormonal therapies and women’s healthcare. To this end, he headed the teams for Rezulin development for Type 2 diabetes, zenarestat for diabetic neuropathy, and FemHRT for postmenopausal therapy. Dr. Herzig
is a well-known expert in immunopharmacology and has given invited
lectures across the country. He is a member of the Board of Directors
of the Michigan Biotechnology Institute and a past board member
of the Metropolitan Center for High Technology and Michigan Biotechnology
Association, of which he is a founding member and past president.
Dr. Borton has worked extensively with the Small Business Innovative Research (SBIR), Advanced Technology Program (ATP) and Broad Agency Announcement programs offered by the federal government, as well as special programs under the Department of Energy, National Science Foundation, Environmental Protection Agency, Department of Defense and Department of Transportation. He served as a consultant to and director of energy and environmental programs for MERRA, a 501 C3 Michigan organization of state government, universities, utility companies and private industry aimed at bringing research, development and deployment of technology to Michigan. In these efforts, he worked extensively with programs such as the national SBIR program (11 federal agencies), the ATP, the Inventions & Innovations program (US DOE), and the National Industrial Competitiveness Through Energy, Environment, & Economics program (US DOE). Dr. Borton developed and manages the Michigan Industries of the Future Program as a contractor with the Energy Office, Michigan Department of Labor and Economic Growth. This includes technology innovation road-mapping activities with the foundry and forging industries, and joint efforts with the National Center for Manufacturing Sciences working with the steel, heat-treating, and forging industry. He is also the incoming President of ITS Michigan, a 501 C3 public-private partnership (automotive OEMs and suppliers, transportation organizations, consulting and planning organizations) organized in the mid-1990’s to help advance development and applications of intelligent transportation system (ITS) technologies in Michigan. He holds his Ph.D. in Environmental Sciences
and Planning from the University of Michigan. Other degrees that
he holds include a M.S. in Environmental Health Sciences from the
University of Michigan, a Master of Urban Planning from Michigan
State University, and a B.S. in Urban Planning, also from MSU.
Dr. Borton also currently serves on the Board of the Technology
Research Corporation, a subsidiary of the National Center for Manufacturing
Sciences.
|
Sumer
Belbez Pek, M.D. Professor of Internal Medicine, Division of
Endocrinology & Metabolism at the University of Michigan
Medical School in Ann Arbor, Michigan, acts as a biomedical
scientific consultant to the BBC. He is a graduate of the University
of Munich Medical School in Germany. He received training in
Internal Medicine and in Endocrinology & Metabolism at
the University of Michigan. He is certified by the American
Board of Internal Medicine in the specialty of Internal Medicine
and in the subspecialty of Endocrinology & Metabolism;
his clinical practice includes the broad field of endocrinology
and diabetes. He has extensive basic and clinical research
experience, culminating in more than 100 scientific publications
in peer-reviewed journals. For over thirty years, his research
has been funded by the National Institutes of Health (NIH),
various foundations and the pharmaceutical industry.
During
Dr. Jackson’s 30 years of working in the Life Sciences,
he has been an Assistant and Associate Professor at the University
of Michigan Medical School, head of research and development
at three biotechnology companies, one of which he helped found,
and head of drug discovery in the areas of infectious diseases,
cancer, and molecular biology for DuPont (later the DuPont Merck
Pharmaceutical Company) for 10 years. During his tenure at DuPont
Merck, Dr. Jackson also headed the team that was responsible
for development of anti-HIV drugs. This included Sustiva®,
one of the world’s top-selling anti-HIV drugs.
Dr.
Borton has 39 years of experience with developing innovative programs
in areas ranging across environmental science, energy development,
transportation technology, computer systems applications, and urban
problems. He has served on the teaching and research faculties
at both The University of Michigan and Michigan State University.
He currently is working with Department of Energy and State of
Michigan programs to improve industrial energy and manufacturing
processes, as well as advancements in the areas of intelligent
transportation systems (vehicular and infrastructure), key areas
in the next stage of change in both transportation and security
technologies. Dr. Borton is currently President of the consulting
firm, Thomas Borton Associates, Inc. 
Dr. Özdemir
has received his Ph.D. in Electrical Engineering from the University
of Michigan in 1998 with specialization in Electromagnetics.
During his graduate studies, Dr. Özdemir carried out research
in numerical electromagnetic modeling, antenna design, mine
detection, and ultrasound and microwave imaging. For the next
4.5 years, he worked as a Sr. Research Engineer and later as
a Group Manager at EMAG Technologies Inc. in charge of developing
software for antenna and microwave circuit design. In 2002,
Dr. Özdemir founded VisualEM Corporation, where he currently
carries out research and development activities funded through
SBIR contracts from the Department of Defense (DoD.) He has
six years of experience in obtaining and managing SBIR contracts
dealing with antenna design and optimization, antenna miniaturization,
and micro-electromechanical systems (MEMS.)